Advertisement

Topics

Darolutamide: Global Drug Analysis 2017 with Forecasts to 2026 – Strong Competition from Xtandi, Zytiga and Apalutamide – ResearchAndMarkets.com

09:04 EST 15 Feb 2018 | Biotech 365

DUBLIN–(BUSINESS WIRE)–The “Drug Analysis: Darolutamide” drug pipelines has been added to ResearchAndMarkets.com’s offering. Darolutamide is a non-steroidal oral androgen receptor (AR) antagonist in development by Bayer for the treatment of prostate cancer. Darolutamide potently inhibits the binding of androgens to … Continue reading

Cet article Darolutamide: Global Drug Analysis 2017 with Forecasts to 2026 – Strong Competition from Xtandi, Zytiga and Apalutamide – ResearchAndMarkets.com est apparu en premier sur Biotech 365.

Original Article: Darolutamide: Global Drug Analysis 2017 with Forecasts to 2026 – Strong Competition from Xtandi, Zytiga and Apalutamide – ResearchAndMarkets.com

NEXT ARTICLE

More From BioPortfolio on "Darolutamide: Global Drug Analysis 2017 with Forecasts to 2026 – Strong Competition from Xtandi, Zytiga and Apalutamide – ResearchAndMarkets.com"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...